Musadiq, M.; Musadiq, M.; Latif, F.; Ng, B.; Azzopardi, M.; Gilead, N.; Needham, A.; Chong, Y.J.
Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life 2025, 15, 903.
https://doi.org/10.3390/life15060903
AMA Style
Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, Needham A, Chong YJ.
Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life. 2025; 15(6):903.
https://doi.org/10.3390/life15060903
Chicago/Turabian Style
Musadiq, Muiz, Mohammed Musadiq, Fozia Latif, Benjamin Ng, Matthew Azzopardi, Noa Gilead, Andrew Needham, and Yu Jeat Chong.
2025. "Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom" Life 15, no. 6: 903.
https://doi.org/10.3390/life15060903
APA Style
Musadiq, M., Musadiq, M., Latif, F., Ng, B., Azzopardi, M., Gilead, N., Needham, A., & Chong, Y. J.
(2025). Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life, 15(6), 903.
https://doi.org/10.3390/life15060903
